Xcovery, a US Affiliate of China's Betta, Acquires Majority Stake in Meryx
publication date: Dec 7, 2021
Xcovery, a Florida oncology biopharma, acquired a controlling stake in Meryx, a clinical stage North Carolina immuno-oncology company. Xcovery is backed largely by Betta Pharma of Hangzhou, which has formed several partnerships with western companies. Meryx develops small molecule, oral inhibitors of Mer receptor tyrosine kinases (RTK) that lower tumor growth and promote macrophage activity in hematologic and solid malignancies. Xcovery believes there are synergies between the two companies. Terms of the agreement were not disclosed. More details....
Stock Symbol: (SHZ: 300558)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.